The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The immunomodulatory impacts of endocrine therapy on host immunity in early-stage hormone receptor positive, HER2 negative breast cancer.
 
Sarah L. Sammons
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Foundation Medicine; Loxo/Lilly; Novartis; Pfizer; Relay Therapeutics; Sermonix Pharmaceuticals
Research Funding - AstraZeneca/MedImmune (Inst); Lilly (Inst); Relay Therapeutics (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst)
 
Susan Faye Dent
Honoraria - Novartis
Consulting or Advisory Role - AstraZeneca; BMS US; Gilead Sciences; Myocardial Solutions; Novartis; Pfizer
Research Funding - Novartis (Inst)
 
Ching-Yi Chang
No Relationships to Disclose
 
Siyao Liu
No Relationships to Disclose
 
Isaac Chan
No Relationships to Disclose
 
Kent J. Weinhold
No Relationships to Disclose
 
Charles M. Perou
Leadership - GeneCentric
Stock and Other Ownership Interests - Bioclassifier; GeneCentric; Reveal Genomics
Consulting or Advisory Role - Bioclassifier; GeneCentric; NanoString Technologies; Reveal Genomics; Veracyte
Patents, Royalties, Other Intellectual Property - royalties from PAM50 breast cancer gene patent application, and from lung gene signature patent
 
Donald P. McDonnell
Employment - Duke University
Stock and Other Ownership Interests - G1 Therapeutics; Rappta Therapeutics; X-RAD Therapeutics; Zentalis
Consulting or Advisory Role - Bristol-Myers Squibb; G1 therapeutics; Rappta Therapeutics; zentalis
Research Funding - Bristol-Myers Squibb; LQT Therapeutics; Novartis; Rappta Therapeutics; Ribometrix; Zentalis
Patents, Royalties, Other Intellectual Property - I am an inventor on two patents (assigned to Duke) that covers the use of Lasofoxifene for ESR1 mutant breast cancers. Licensed to Sermonix; Inventor on two patents (Assigned to Duke) licensed to Radius Health covering the use of Rad1901 for Breast cancer.
Travel, Accommodations, Expenses - Bristol-Myers Squibb